Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 60

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 60
---
Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations,
and supply chain. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles. Mr. Novack received a
B.S. in Biology from State University of New York and an M.B.A. from Columbia University.

John L. Slebir – Senior Vice President, General Counsel

Mr. Slebir joined Dynavax in June 2021 and currently serves as Senior
Vice President, General Counsel. Mr. Slebir has more than 20 years of experience in life sciences and 30 years of corporate law practice.
Prior to Dynavax, Mr. Slebir worked at VIVUS, Inc., a biopharmaceutical company, from 2009 to June 2021 in roles of increasing responsibility
within the organization. In his final role at VIVUS, Mr. Slebir served as Senior Vice President, Business Development, General Counsel,
Chief Compliance Officer, and Corporate Secretary. While at VIVUS, Mr. Slebir was involved in broad aspects of the company’s commercial
and clinical development partnering efforts, commercial and supply chain alliance management, corporate governance, securities laws and
periodic reporting, risk management, commercial and regulatory compliance and submissions, director and executive compensation, and intellectual
property protection. Before joining VIVUS, Mr. Slebir served for over 10 years as an attorney at Wilson Sonsini Goodrich & Rosati,
P.C., specializing in corporate securities and corporate governance. Mr. Slebir holds a B.A. in Communications from San Diego State University
and a J.D. from Santa Clara University School of Law.

| 43 |

Robert Janssen, M.D. – Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs

Dr. Janssen was appointed Chief Medical Officer and Senior Vice President,
Clinical Development, Medical and Regulatory Affairs in January 2018. Dr. Janssen was appointed Chief Medical Officer and Vice President,
Clinical Development and Regulatory Affairs in July 2013. He served as Dynavax’s Vice President, Medical Affairs since November
2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively
involved with Phase 3 clinical development of HEPLISAV-B and its U.S. and European licensing applications. Prior to joining Dynavax,